Pricing Log in Create free account
Friday 6 November 2026 Export TXG’s income statement to Excel — free account

10x Genomics

TXG Healthcare Medical Devices

10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.

Revenue
+1.12%
EPS
+31.8%
Free cash flow
−4.61%

Quarter to September 2026, against a year earlier

58.74 0.68 +1.17%
Market cap
$7.6B
P/E
0.0×
Fwd P/E
−95.9×
Dividend yield
—
F-score
6/9
Altman Z
3.99
Beneish M
−3.23
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Insider Decisions last twelve months

Sold, $m 16.24
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — 4 2 1 3 2 — 7 4 — —
Insider Ownership 11.20%

Capital & Financial Ratios $m

Size
Market Cap 7,560.00
Revenue ttm 618.58
Net income ttm (67.08)
Free cash flow ttm 93.77
Net debt Q (575.68)
Valuation
P/E 0.00
Forward P/E (95.90) (negative: loss-making)
Price / sales 12.40 (above 10: high)
Forward P/S Powerpack
Price / FCF 82.67
Price / book 9.15 (above 6: high)
Financial health
Current ratio Q 5.12 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 10,747.33
Growth
Revenue growth Q +1.12% (above 0%: growing)
Operating income growth Q +50.20% (above 0%: growing)
EPS, this year −106.36% (below 0%: weak)
EPS, next year A +0.27%
Revenue, next year A −3.46% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A −5.06% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 11.5×, against a ten-year median of 9.6×; over the ten years it ranged from 1.0× in 2025 to 62.8× in 2021.
P/S against its own 10 years 62.31%
10-year low 10-year high
P/B against its own 10 years 63.47%
10-year low 10-year high
EV/Sales against its own 10 years 62.14%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 389 393 523 576
Receivables 115 88 82 —
Inventory 74 83 56 65
Other — — — —
596 584 684 719
2023 2024 2025 Q'26
Payables 16 13 13 22
ST’ Debt — — — —
Other — — 23 12
127 118 153 140

Compound Annual Growth %

10y 5y 3y
Sales — 16.55% 7.57%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 1.50% (0.39%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.23 Actual −0.14

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.27 −0.22 Beat by 0.05
Q4 FY25 −0.19 −0.13 Beat by 0.06
Q1 FY26 −0.29 −0.10 Beat by 0.19
Q2 FY26 −0.23 −0.14 Beat by 0.09
Q3 FY26 −0.29 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.10) (0.14) (0.15) — —
’25 (0.28) 0.28 (0.22) (0.13) (0.35)
’24 (0.50) (0.32) (0.30) (0.40) (1.52)
’23 (0.44) (0.53) (0.79) (0.41) (2.18)
’22 (0.38) (0.57) (0.37) (0.15) (1.46)
’21 (0.11) (0.10) (0.15) (0.16) (0.53)
’20 (0.22) (0.41) (0.65) (3.87) (5.37)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 151 151 151 — —
’25 155 173 149 166 643
’24 141 153 152 165 611
’23 134 147 154 184 619
’22 114 115 131 156 516
’21 106 116 125 144 490
’20 72 43 72 112 299
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 26 17 16 — —
’25 34 18 43 41 136
’24 (16) 7 22 (7) 7
’23 (4) (12) (25) 26 (15)
’22 (21) (17) (10) 14 (34)
’21 (4) 3 (26) 6 (21)
’20 (3) (30) (56) (130) (218)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 25 15 15 — —
’25 32 16 43 39 130
’24 (19) 4 18 (9) (7)
’23 (9) (37) (41) 22 (65)
’22 (49) (44) (46) (26) (165)
’21 (43) (11) (46) (22) (123)
’20 (11) (36) (57) (152) (256)
Fiscal quarters ending in the months shown.

Valuation

The price implies free cash flow after share-based pay growing 30.1% a year for ten years.

Implied
30.1%
Open the model

Target Price Range

Analyst price targets

Recommendation Rating

2.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — 71 146 246 299 490 516 619 611 643 619 +31.7% 621 683 756 +5.6%
Gross margin, % — 85.14 80.41 75.18 80.44 84.89 76.69 66.15 67.86 69.05 71.88 (16.1) pt
EBT — (19) (112) (31) (534) (54) (162) (249) (178) (40) (65) +9.9%
EBT margin, % — (26.36) (76.82) (12.62) (178.85) (10.95) (31.36) (40.21) (29.09) (6.21) (10.53) +20.2 pt
Net income — (19) (112) (31) (543) (58) (166) (255) (183) (44) (67) +11.1%
Per share, $
Per share, $ Revenue — 6.13 10.93 6.29 2.95 4.44 4.54 5.28 5.07 5.15 4.73 (2.2%)
Earnings — (1.62) (8.40) (0.80) (5.37) (0.53) (1.46) (2.18) (1.52) (0.35) (0.52) (17.4%)
Cash flow — (0.92) (5.71) 0.89 (2.15) (0.19) (0.30) (0.13) 0.06 1.09 0.76 n/m
Capex — (0.32) (0.50) (1.09) (0.38) (0.92) (1.16) (0.42) (0.11) (0.05) (0.05) (21.3%)
Free cash flow — (1.25) (6.21) (0.21) (2.53) (1.11) (1.45) (0.55) (0.06) 1.04 0.72 n/m
Book value — 0.00 1.74 10.75 7.31 7.41 7.08 6.32 5.90 6.38 6.41 n/m
Shares, m — 12 13 39 101 110 114 117 120 125 128 +34.6%
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — 0.00 0.00 29.78 47.93 33.51 7.79 10.28 2.83 3.17 12.40 15.0
P/B — 0.00 0.00 17.43 19.38 20.11 4.99 8.59 2.44 2.56 9.15 8.4
EV/Sales — 0.00 0.00 28.17 45.75 32.37 7.01 9.70 2.24 2.40 11.52 14.2
EV/FCF — 0.00 (7.40) (853.68) (53.71) (129.46) (21.90) (92.75) (203.00) 11.93 76.78 (150.0)
Cash, $m
Cash, $m Operating cash flow — (11) (76) 35 (218) (21) (34) (15) 7 136 100 n/m
Capex — (4) (7) (43) (38) (101) (132) (50) (13) (6) (6) +5.9%
Free cash flow — (14) (83) (8) (256) (123) (165) (65) (7) 130 94 n/m
Balance, $m
Balance, $m Working capital — 46 74 418 656 637 504 469 467 531 578 +35.8%
Net debt — 121 (35) (394) (680) (588) (433) (389) (393) (523) (576) n/m
Shareholders’ equity — — 23 420 739 818 806 741 710 796 838 +65.7%
Returns, %
Returns, % ROA — (18.76) (180.97) (8.56) (70.70) (5.98) (16.21) (25.59) (19.39) (4.44) (6.42) +14.3 pt
ROIC — (9.49) 0.00 (74.54) (566.77) (14.26) (28.13) (47.06) (38.39) (13.97) (17.20) (4.5) pt
ROE — 11.27 67.56 (31.24) (93.64) (7.48) (20.45) (32.98) (25.17) (5.78) (8.27) (17.0) pt
People
People Employees — — 401 200 290 417 453 451 410 473 — +2.4%
Revenue/emp, $m — 0.00 0.36 1.23 1.03 1.18 1.14 1.37 1.49 1.36 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Business profile

Updated

10x Genomics is a life sciences technology company that sells instruments, consumables and software to researchers studying biology. Its customers include academic and government research institutions, biotechnology and biopharmaceutical companies. The company was incorporated in 2012 and is headquartered in Pleasanton, California. Serge Saxonov is its chief executive officer.

Its tools help scientists examine biological material at the level of individual cells or map where molecules and cells sit within a tissue sample. Researchers use the resulting data in fields including oncology, immunology and neuroscience. The company markets its products for research use only, not for diagnostic procedures.

10x Genomics vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SNN Smith & Nephew SNATS, Inc. $13.4B 38.9× 18.9× +7.99% (above 0%: growing) −14.23% (below 0%: shrinking) +293.94% (above 0%: growing) 69.42% 0.00% Compare
PEN Penumbra, Inc. $12.7B 80.3× 68.7× +15.64% (above 0%: growing) −8.29% (below 0%: shrinking) −37.16% (below 0%: shrinking) 68.34% 12.37% Compare
GMED Globus Medical, Inc. $10.9B 19.5× 18.8× −0.69% (below 0%: shrinking) +19.32% (above 0%: growing) +10.10% (above 0%: growing) 69.50% 23.25% Compare
PODD Insulet Corporation $10.8B 25.2× 24.4× +19.21% (above 0%: growing) +64.06% (above 0%: growing) −29.81% (below 0%: shrinking) 75.07% 22.54% Compare
BIO.B Bio-Rad Laboratories, Inc. $10.3B 9.9× — +0.52% (above 0%: growing) n/m +8.07% (above 0%: growing) 50.06% (7.57%) Compare
BIO Bio-Rad Laboratories, Inc. $9.9B 9.7× 44.7× +0.52% (above 0%: growing) n/m +8.07% (above 0%: growing) 50.06% (7.57%) Compare
BRKR Bruker Corporation $8.9B — (loss-making) — (loss-making) +1.57% (above 0%: growing) n/m +278.74% (above 0%: growing) 49.12% (10.41%) Compare
TXG 10x Genomics $7.6B — (loss-making) — (loss-making) −12.65% (below 0%: shrinking) n/m −4.61% (below 0%: shrinking) 74.48% (12.95%)
HAE Haemonetics Corporation $5.7B 54.5× 30.2× +9.30% (above 0%: growing) +25.93% (above 0%: growing) +20.37% (above 0%: growing) 61.75% 21.00% Compare
Median of peers $10.6B 25.2× 27.3× +4.78% +19.32% +9.09% 65.05% 6.19%

All 149 Medical Devices stocks →

From the latest earnings call

Updated

  • On the Q1 call, CEO Serge Saxonov said customer response to Atara exceeded his expectations and that anticipated changes in spatial ordering were incorporated into the outlook.
  • CFO Adam Taich said some customers had delayed Xenium purchases while waiting for Atara and that initial Atara production capacity would be limited.

Largest institutional holders 13F, quarter to 30 June 2026

Held by institutions 95.26%
Held by the ten largest 58.79%
Holder Shares Stake Change
Fidelity (FMR) 17.63m 13.53% −111.71k
Vanguard 13.11m 10.06% −64.01k
BlackRock 10.80m 8.29% +724.16k
ARK Investment Management LLC 10.00m 7.68% −1.71m
T. Rowe Price 5.81m 4.46% +4.36m
Quantinno Capital Management LP 5.47m 4.20% +57.94k
Sumitomo Mitsui Trust 4.19m 3.22% −915.59k
Morgan Stanley 3.35m 2.57% +695.56k
Goldman Sachs 3.15m 2.42% −822.94k
Geode Capital Management 3.08m 2.37% +178.56k
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.

Pay and ownership Proxy statement filed 24 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 6.33m 6.79m 11.52
2024 7.93m (21.17m) 10.14
2023 8.29m 17.35m 39.52
2022 18.81m (14.31m) 25.73
2021 11.70m 20.81m 105.20

Ownership

Directors and executive officers, together 37.90% of the votes
Serge Saxonov 14.30% of the votes
Benjamin J. Hindson 13.70% of the votes
Fidelity and affiliated entities 12.10% of the votes
John R. Stuelpnagel 9.80% of the votes
ARK Investment Management LLC 5.40% of the votes
BlackRock, Inc. 3.90% of the votes
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

10x Genomics (TXG) Latest News

6 Nov

Impact 3 · · Zacks
Impact 3 · · Zacks
Impact 3 · · MarketBeat transcript
Impact 3 · · The Motley Fool transcript

5 Nov

Impact 3 · · StockStory
Impact 3 · · PR Newswire

29 Oct

Impact 3 · · Zacks

28 Oct

Impact 3 · · Simply Wall St.

27 Oct

Impact 3 · · PR Newswire

19 Oct

Impact 3 · · StockStory

16 Oct

Impact 4 · · Simply Wall St.

15 Oct

Impact 3 · · StockStory

9 Oct

Impact 3 · · StockStory

8 Oct

Impact 4 · · Zacks

7 Oct

Impact 4 · · PR Newswire

5 Oct

Impact 4 · · Simply Wall St.

30 Sep

Impact 4 · · Zacks

29 Sep

Impact 4 · · PR Newswire
Impact 4 · · PR Newswire

25 Sep

Impact 3 · · Trefis

19 Sep

Impact 3 ·

1 Sep

Impact 3 ·

28 Aug

Impact 4 ·

18 Aug

Impact 4 ·

16 Aug

Impact 3 ·

15 Aug

Impact 3 ·

14 Aug

Impact 3 · · The Motley Fool transcript

9 Aug

Impact 4 ·

7 Aug

Impact 3 · · MarketBeat transcript
Impact 3 ·

TXG metrics, ten years each

stockrow.com/TXG · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com